BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, Gaymard A, Ferré V, Hartard C, Plantier JC, Thibault V, Marlet J, Montes B, Bouiller K, Lescure FX, Timsit JF, Faure E, Poissy J, Chidiac C, Raffi F, Kimmoun A, Etienne M, Richard JC, Tattevin P, Garot D, Le Moing V, Bachelet D, Tardivon C, Duval X, Yazdanpanah Y, Mentré F, Laouénan C, Visseaux B, Guedj J; French COVID Cohort Investigators and French Cohort Study groups. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci U S A 2021;118:e2017962118. [PMID: 33536313 DOI: 10.1073/pnas.2017962118] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 24.0] [Reference Citation Analysis]
Number Citing Articles
1 Gaitán-Duarte HG, Álvarez-Moreno C, Rincón-Rodríguez CJ, Yomayusa-González N, Cortés JA, Villar JC, Bravo-Ojeda JS, García-Peña A, Adarme-Jaimes W, Rodríguez-Romero VA, Villate-Soto SL, Buitrago G, Chacón-Sarmiento J, Macias-Quintero M, Vaca CP, Gómez-Restrepo C, Rodríguez-Malagón N. Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine 2022;43:101242. [PMID: 34957385 DOI: 10.1016/j.eclinm.2021.101242] [Reference Citation Analysis]
2 Farhang-sardroodi S, Ghaemi MS, Craig M, Ooi HK, Heffernan JM. . MBE 2022;19:5813-31. [DOI: 10.3934/mbe.2022272] [Reference Citation Analysis]
3 Wu Y, Dang H, Park SG, Chen L, Choo J. SERS-PCR assays of SARS-CoV-2 target genes using Au nanoparticles-internalized Au nanodimple substrates. Biosens Bioelectron 2022;197:113736. [PMID: 34741957 DOI: 10.1016/j.bios.2021.113736] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
4 Ke R, Zitzmann C, Ho DD, Ribeiro RM, Perelson AS. In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness. Proc Natl Acad Sci U S A 2021;118:e2111477118. [PMID: 34857628 DOI: 10.1073/pnas.2111477118] [Reference Citation Analysis]
5 Iwanami S, Ejima K, Kim KS, Noshita K, Fujita Y, Miyazaki T, Kohno S, Miyazaki Y, Morimoto S, Nakaoka S, Koizumi Y, Asai Y, Aihara K, Watashi K, Thompson RN, Shibuya K, Fujiu K, Perelson AS, Iwami S, Wakita T. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med 2021;18:e1003660. [PMID: 34228712 DOI: 10.1371/journal.pmed.1003660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 AlQahtani M, Kumar N, Aljawder D, Abdulrahman A, Alnashaba F, Fayyad MA, Alshaikh F, Alsahaf F, Saeed S, Almahroos A, Abdulrahim Z, Otoom S, Atkin SL. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. Sci Rep 2022;12:4925. [PMID: 35322077 DOI: 10.1038/s41598-022-08794-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Swan DA, Goyal A, Bracis C, Moore M, Krantz E, Brown E, Cardozo-Ojeda F, Reeves DB, Gao F, Gilbert PB, Corey L, Cohen MS, Janes H, Dimitrov D, Schiffer JT. Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. Viruses 2021;13:1921. [PMID: 34696352 DOI: 10.3390/v13101921] [Reference Citation Analysis]
8 Sourander B, Andersson LM, Brink M, Yilmaz A, Sundell N, Marklund E, Nilsson S, Lindh M, Robertson J, Gisslén M. No effect of remdesivir or betamethasone on upper respiratory tract SARS-CoV-2 RNA kinetics in hospitalised COVID-19 patients: a retrospective observational study. Infect Dis (Lond) 2022;:1-10. [PMID: 35708280 DOI: 10.1080/23744235.2022.2081716] [Reference Citation Analysis]
9 Kirkby C. A model of infection and immune response to low dose radiation. Int J Radiat Biol 2022;:1-14. [PMID: 34995150 DOI: 10.1080/09553002.2022.2020361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Larionova R, Byvaltsev K, Kravtsova О, Takha E, Petrov S, Kazarian G, Valeeva A, Shuralev E, Mukminov M, Renaudineau Y, Arleevskaya M. SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases. Journal of Translational Autoimmunity 2022;5:100154. [DOI: 10.1016/j.jtauto.2022.100154] [Reference Citation Analysis]
11 Baabdulla AA, Now H, Park JA, Kim WJ, Jung S, Yoo JY, Hillen T. Homogenization of a reaction diffusion equation can explain influenza A virus load data. J Theor Biol 2021;527:110816. [PMID: 34161792 DOI: 10.1016/j.jtbi.2021.110816] [Reference Citation Analysis]
12 Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, Gallagher N, Luo CH, Jarrett J, Conte A, Liu T, Farjo M, Walden KKO, Rendon G, Fields CJ, Wang L, Fredrickson R, Edmonson DC, Baughman ME, Chiu KK, Choi H, Scardina KR, Bradley S, Gloss SL, Reinhart C, Yedetore J, Quicksall J, Owens AN, Broach J, Barton B, Lazar P, Heetderks WJ, Robinson ML, Mostafa HH, Manabe YC, Pekosz A, McManus DD, Brooke CB. Daily sampling of early SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. medRxiv 2021:2021. [PMID: 34282424 DOI: 10.1101/2021.07.12.21260208] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 17.0] [Reference Citation Analysis]
13 Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, Kuzmina NA, Freyn AW, Snitselaar JL, Gonçalves A, Caniels TG, Burger JA, Poniman M, Chesnais V, Diry S, Iershov A, Ronk AJ, Jangra S, Rathnasinghe R, Brouwer P, Bijl T, van Schooten J, Brinkkemper M, Liu H, Yuan M, Mire CE, van Breemen MJ, Contreras V, Naninck T, Lemaître J, Kahlaoui N, Relouzat F, Chapon C, Ho Tsong Fang R, McDanal C, Osei-Twum M, St-Amant N, Gagnon L, Montefiori DC, Wilson IA, Ginoux E, de Bree GJ, García-Sastre A, Schotsaert M, Coughlan L, Bukreyev A, van der Werf S, Guedj J, Sanders RW, van Gils MJ, Le Grand R. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Res Sq 2021:rs. [PMID: 33619476 DOI: 10.21203/rs.3.rs-235272/v1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
14 Roquebert B, Haim-Boukobza S, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, Burrel S, Alizon S, Sofonea MT. SARS-CoV-2 variants of concern are associated with lower RT-PCR amplification cycles between January and March 2021 in France. Int J Infect Dis 2021;113:12-4. [PMID: 34601145 DOI: 10.1016/j.ijid.2021.09.076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Frank TD. Eigenvalue analysis of SARS-CoV-2 viral load data: illustration for eight COVID-19 patients. Int J Data Sci Anal. [DOI: 10.1007/s41060-022-00319-y] [Reference Citation Analysis]
16 Labhardt ND, Smit M, Petignat I, Perneger T, Marinosci A, Ustero P, Diniz Ribeiro MP, Ragozzino S, Nicoletti GJ, Faré PB, Andrey DO, Jacquerioz F, Lebowitz D, Agoritsas T, Meyer B, Spechbach H, Salamun J, Guessous I, Chappuis F, Kaiser L, Decosterd LA, Grinsztejn B, Bernasconi E, Cardoso SW, Calmy A, Team FTCS. Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine 2021;42:101188. [PMID: 34778734 DOI: 10.1016/j.eclinm.2021.101188] [Reference Citation Analysis]
17 Gonçalves A, Maisonnasse P, Donati F, Albert M, Behillil S, Contreras V, Naninck T, Marlin R, Solas C, Pizzorno A, Lemaitre J, Kahlaoui N, Terrier O, Ho Tsong Fang R, Enouf V, Dereuddre-Bosquet N, Brisebarre A, Touret F, Chapon C, Hoen B, Lina B, Rosa Calatrava M, de Lamballerie X, Mentré F, Le Grand R, van der Werf S, Guedj J. SARS-CoV-2 viral dynamics in non-human primates. PLoS Comput Biol 2021;17:e1008785. [PMID: 33730053 DOI: 10.1371/journal.pcbi.1008785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Challenger JD, Foo CY, Wu Y, Yan AWC, Marjaneh MM, Liew F, Thwaites RS, Okell LC, Cunnington AJ. Modelling upper respiratory viral load dynamics of SARS-CoV-2. BMC Med 2022;20:25. [PMID: 35022051 DOI: 10.1186/s12916-021-02220-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
19 Contreras C, Newby JM, Hillen T. Personalized Virus Load Curves for Acute Viral Infections. Viruses 2021;13:1815. [PMID: 34578396 DOI: 10.3390/v13091815] [Reference Citation Analysis]
20 Ke R, Zitzmann C, Ho DD, Ribeiro RM, Perelson AS. In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness. medRxiv 2021:2021. [PMID: 34230935 DOI: 10.1101/2021.06.26.21259581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Elaiw A, Alsaedi A, Hobiny A. Global stability of a delayed SARS-CoV-2 reactivation model with logistic growth, antibody immunity and general incidence rate. Alexandria Engineering Journal 2022. [DOI: 10.1016/j.aej.2022.05.034] [Reference Citation Analysis]
22 Yin Y, Xi Y, Xu C, Sun Q. The Basic Reproduction Number and Delayed Action of T Cells for Patients Infected with SARS-CoV-2. Mathematics 2022;10:2017. [DOI: 10.3390/math10122017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Moses ME, Hofmeyr S, Cannon JL, Andrews A, Gridley R, Hinga M, Leyba K, Pribisova A, Surjadidjaja V, Tasnim H, Forrest S. Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection. PLoS Comput Biol 2021;17:e1009735. [PMID: 34941862 DOI: 10.1371/journal.pcbi.1009735] [Reference Citation Analysis]
24 Mizrahi B, Bivas-Benita M, Kalkstein N, Akiva P, Yanover C, Yehezkelli Y, Kessler Y, Alon SH, Rubin E, Chodick G. Results of an early second PCR test performed on SARS-CoV-2 positive patients may support risk assessment for severe COVID-19. Sci Rep 2021;11:20463. [PMID: 34650138 DOI: 10.1038/s41598-021-99671-5] [Reference Citation Analysis]
25 Lin J, Law R, Korosec CS, Zhou C, Koh WH, Ghaemi MS, Samaan P, Ooi HK, Matveev V, Yue F, Gingras AC, Estacio A, Buchholz M, Cheatley PL, Mohammadi A, Kaul R, Pavinski K, Mubareka S, McGeer AJ, Leis JA, Heffernan JM, Ostrowski M. Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity. J Virol 2022;:e0050922. [PMID: 35699447 DOI: 10.1128/jvi.00509-22] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kim KS, Iwanami S, Oda T, Fujita Y, Kuba K, Miyazaki T, Ejima K, Iwami S. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. Life Sci Alliance 2021;4:e202101049. [PMID: 34344719 DOI: 10.26508/lsa.202101049] [Reference Citation Analysis]
27 Blanco-Rodríguez R, Du X, Hernández-Vargas E. Computational simulations to dissect the cell immune response dynamics for severe and critical cases of SARS-CoV-2 infection. Comput Methods Programs Biomed 2021;211:106412. [PMID: 34610492 DOI: 10.1016/j.cmpb.2021.106412] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Xu J, Kerr L, Jiang Y, Suo W, Zhang L, Lao T, Chen Y, Zhang Y. Rapid Antigen Diagnostics as Frontline Testing in the COVID‐19 Pandemic. Small Science. [DOI: 10.1002/smsc.202200009] [Reference Citation Analysis]
29 Rouka E, Kotsiou OS, Perlepe G, Pagonis A, Pantazopoulos I, Gourgoulianis KI. Temporal Associations of the SARS-CoV-2 NP Antigen and Anti-Spike Total Ig Levels with Laboratory Parameters in a Greek Cohort of Hospitalized COVID-19 Patients. Can Respir J 2021;2021:6590528. [PMID: 34621457 DOI: 10.1155/2021/6590528] [Reference Citation Analysis]
30 Codina H, Vieitez I, Gutierrez-Valencia A, Skouridou V, Martínez C, Patiño L, Botero-Gallego M, Trujillo-Rodríguez M, Serna-Gallego A, Muñoz-Muela E, Bobillo MM, Pérez A, Cabrera-Alvar JJ, Crespo M, O'Sullivan CK, Ruiz-Mateos E, Poveda E. Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19. Microorganisms 2021;9:2259. [PMID: 34835384 DOI: 10.3390/microorganisms9112259] [Reference Citation Analysis]
31 Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses 2021;13:1642. [PMID: 34452507 DOI: 10.3390/v13081642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
32 Forgacs D, Silva-moraes V, Sautto GA, Hanley HB, Gattiker JL, Jefferson AM, Kolhe R, Ross TM. The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination. Vaccines 2022;10:696. [DOI: 10.3390/vaccines10050696] [Reference Citation Analysis]
33 Zhu Y, Oishi W, Saito M, Kitajima M, Sano D. Early Warning of COVID-19 in Tokyo via Wastewater-based Epidemiology: How Feasible It Really Is? J of Wat & Envir Tech 2021;19:170-83. [DOI: 10.2965/jwet.21-024] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Conway JM, Abel Zur Wiesch P. Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized? Pharmaceutics 2021;13:1181. [PMID: 34452142 DOI: 10.3390/pharmaceutics13081181] [Reference Citation Analysis]
35 Alizon S, Sofonea MT. SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs. J Evol Biol 2021. [PMID: 34196431 DOI: 10.1111/jeb.13896] [Reference Citation Analysis]
36 Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, Kuzmina NA, Freyn AW, Snitselaar JL, Gonçalves A, Caniels TG, Burger JA, Poniman M, Bontjer I, Chesnais V, Diry S, Iershov A, Ronk AJ, Jangra S, Rathnasinghe R, Brouwer PJM, Bijl TPL, van Schooten J, Brinkkemper M, Liu H, Yuan M, Mire CE, van Breemen MJ, Contreras V, Naninck T, Lemaître J, Kahlaoui N, Relouzat F, Chapon C, Ho Tsong Fang R, McDanal C, Osei-Twum M, St-Amant N, Gagnon L, Montefiori DC, Wilson IA, Ginoux E, de Bree GJ, García-Sastre A, Schotsaert M, Coughlan L, Bukreyev A, van der Werf S, Guedj J, Sanders RW, van Gils MJ, Le Grand R. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nat Commun 2021;12:6097. [PMID: 34671037 DOI: 10.1038/s41467-021-26354-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Vaidya NK, Bloomquist A, Perelson AS. Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets. Viruses 2021;13:1635. [PMID: 34452499 DOI: 10.3390/v13081635] [Reference Citation Analysis]
38 Nourbakhsh S, Fazil A, Li M, Mangat CS, Peterson SW, Daigle J, Langner S, Shurgold J, D’aoust P, Delatolla R, Mercier E, Pang X, Lee BE, Stuart R, Wijayasri S, Champredon D. A Wastewater-Based Epidemic Model for SARS-CoV-2 with Application to Three Canadian Cities. Epidemics 2022. [DOI: 10.1016/j.epidem.2022.100560] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
39 Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, Gallagher N, Luo CH, Jarrett J, Zhou R, Conte A, Liu T, Farjo M, Walden KKO, Rendon G, Fields CJ, Wang L, Fredrickson R, Edmonson DC, Baughman ME, Chiu KK, Choi H, Scardina KR, Bradley S, Gloss SL, Reinhart C, Yedetore J, Quicksall J, Owens AN, Broach J, Barton B, Lazar P, Heetderks WJ, Robinson ML, Mostafa HH, Manabe YC, Pekosz A, McManus DD, Brooke CB. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol 2022;7:640-52. [PMID: 35484231 DOI: 10.1038/s41564-022-01105-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
40 Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, Marks M, Guedj J. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. Elife 2021;10:e69302. [PMID: 34569939 DOI: 10.7554/eLife.69302] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Mancilla-Galindo J, Kammar-García A, Martínez-Esteban A, Meza-Comparán HD, Mancilla-Ramírez J, Galindo-Sevilla N. COVID-19 patients with increasing age experience differential time to initial medical care and severity of symptoms. Epidemiol Infect 2021;149:e230. [PMID: 34674789 DOI: 10.1017/S095026882100234X] [Reference Citation Analysis]
42 Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2021:S1473-3099(21)00485-0. [PMID: 34534511 DOI: 10.1016/S1473-3099(21)00485-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Alizon S, Selinger C, Sofonea MT, Haim-Boukobza S, Giannoli JM, Ninove L, Pillet S, Thibault V, de Rougemont A, Tumiotto C, Solis M, Stephan R, Bressollette-Bodin C, Salmona M, L'Honneur AS, Behillil S, Lefeuvre C, Dina J, Hantz S, Hartard C, Veyer D, Delagrèverie HM, Fourati S, Visseaux B, Henquell C, Lina B, Foulongne V, Burrel S; SFM COVID-19 study group. Epidemiological and clinical insights from SARS-CoV-2 RT-PCR crossing threshold values, France, January to November 2020. Euro Surveill 2022;27. [PMID: 35144725 DOI: 10.2807/1560-7917.ES.2022.27.6.2100406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Parienti JJ, Prazuck T, Peyro-Saint-Paul L, Fournier A, Valentin C, Brucato S, Verdon R, Sève A, Colin M, Lesne F, Guinard J, Ar Gouilh M, Dina J, Vabret A, Hocqueloux L. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. EClinicalMedicine 2021;38:100993. [PMID: 34222849 DOI: 10.1016/j.eclinm.2021.100993] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
45 Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci Alliance 2022;5:e202101200. [PMID: 35012962 DOI: 10.26508/lsa.202101200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
46 Proverbio D, Kemp F, Magni S, Ogorzaly L, Cauchie HM, Gonçalves J, Skupin A, Aalto A. Model-based assessment of COVID-19 epidemic dynamics by wastewater analysis. Sci Total Environ 2022;827:154235. [PMID: 35245552 DOI: 10.1016/j.scitotenv.2022.154235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 [DOI: 10.1101/2021.05.26.21257835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Padmanabhan P, Desikan R, Dixit NM. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. Nat Comput Sci 2022;2:123-31. [DOI: 10.1038/s43588-022-00198-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
49 Fais F, Juskeviciene R, Francardo V, Mateos S, Guyard M, Viollet C, Constant S, Borelli M, Hohenfeld IP. Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia. Int J Mol Sci 2022;23:4062. [PMID: 35409423 DOI: 10.3390/ijms23074062] [Reference Citation Analysis]
50 Fain BG, Dobrovolny HM. GPU acceleration and data fitting: Agent-based models of viral infections can now be parameterized in hours. Journal of Computational Science 2022. [DOI: 10.1016/j.jocs.2022.101662] [Reference Citation Analysis]
51 Messin L, Puyraveau M, Benabdallah Y, Lepiller Q, Gendrin V, Zayet S, Klopfenstein T, Toko L, Pierron A, Royer PY. COVEVOL: Natural Evolution at 6 Months of COVID-19. Viruses 2021;13:2151. [PMID: 34834958 DOI: 10.3390/v13112151] [Reference Citation Analysis]
52 Goyal A, Reeves DB, Schiffer JT. Multi-scale modelling reveals that early super-spreader events are a likely contributor to novel variant predominance. J R Soc Interface 2022;19:20210811. [PMID: 35382576 DOI: 10.1098/rsif.2021.0811] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]